Expanded access to tecentriq for people whose dose failed quality control
Part of Cancer clinical trials.
This trial gives people who have been prescribed TECELRA (a cell therapy for certain cancers) a chance to receive their dose even if it didn't meet quality standards. It's for patients who have no other way to get this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already been prescribed a treatment called TECELRA (tecentriq).
- Your doctor must have found that your made dose didn't meet quality standards, and making a new one isn't possible or safe.
- You must be able to have another cell collection (leukapheresis) — or your doctor says it's not safe to repeat.
- You must not have the genetic type HLA-A*02:05P, because TECELRA is not safe for people with that type.
- You must be healthy enough to receive this treatment, and if you could become pregnant, you need a negative pregnancy test within 7 days of starting chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a new therapy for children and young adults with specific types of cancer that have been treated with chemotherapy before. It may help by targeting cancer features in the tumor and using your immune system in a controlled way.
This trial tests a drug called N-803 for people with synovial sarcoma or myxoid/round cell liposarcoma that has gotten worse after T-cell therapy. N-803 may help the immune system fight the cancer, and the study will see if it can slow or stop the cancer from growing.
This program provides access to AMTAGVI, a personalized cell therapy for melanoma, for patients whose manufactured product did not meet commercial release standards but was deemed safe. It aims to offer treatment when no other options are available.
This trial gives people access to a specially made CAR T-cell therapy (a treatment that uses your own immune cells to fight cancer) that didn't pass the usual quality checks but is still considered safe. It's for patients who have no other good options and are already set to receive this treatment.
This trial provides access to a CAR T-cell therapy (ide-cel) that was made for you but didn't meet commercial release standards. It's an expanded access program for patients who have no other options and are stable enough to receive the treatment.
This trial provides access to a CAR T-cell therapy called liso-cel for people whose own treatment batch didn't meet quality standards but who might still benefit. It's a way to receive the therapy when re-making it isn't possible.
Hear when a new Synovial Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.